Diagonal Bio AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DIABIO.ST research report →
Companydiagonalbio.com
Diagonal Bio AB operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was founded in 2020 and is headquartered in Lund, Sweden.
- CEO
- Karin E. Wehlin
- IPO
- 2021
- Employees
- 4
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $20.20M
- P/E
- -2.52
- P/S
- 81.45
- P/B
- 0.68
- EV/EBITDA
- -2.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 281.05%
- Op Margin
- -3008.87%
- Net Margin
- -2984.27%
- ROE
- -27.62%
- ROIC
- -27.24%
Growth & Income
- Revenue
- $62.00K · 169.57%
- Net Income
- $-9,930,000 · 14.97%
- EPS
- $-0.04 · 87.50%
- Op Income
- $-9,421,000
- FCF YoY
- -62.83%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -1.85
- Avg Volume
- 4.58M
Get TickerSpark's AI analysis on DIABIO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DIABIO.ST Coverage
We haven't published any research on DIABIO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DIABIO.ST Report →